Camcevi FDA Approval History
Last updated by Judith Stewart, BPharm on June 2, 2021.
FDA Approved: Yes (First approved May 26, 2021)
Brand name: Camcevi
Generic name: leuprolide mesylate
Dosage form: Injection
Company: Foresee Pharmaceuticals
Treatment for: Prostate Cancer
Camcevi (leuprolide mesylate) is a ready-to-use, 6-month depot formulation of the approved gonadotropin releasing hormone (GnRH) agonist leuprolide indicated for the treatment of adult patients with advanced prostate cancer.
Development timeline for Camcevi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.